Mankind Pharma Signs Agreement with Takeda
The agreement allows Mankind Pharma to launch the novel drug for treating Gastroesophageal Reflux Disease (GERD) under its trademark.
Mumbai: Mankind Pharma Limited and Takeda Pharmaceutical Company Limited signed a Non-Exclusive Patent License Agreement for commercialising 'Vonoprazan' in the Indian market. The agreement allows Mankind Pharma to launch the novel drug for treating Gastroesophageal Reflux Disease (GERD) under its trademark.
Vonoprazan is a potassium-competitive acid blocker (P-CAB) used for the treatment of acid-related disorders, including Gastroesophageal Reflux Disease (GERD). The drug is effective in treating conditions such as erosive oesophagitis, gastric ulcer, duodenal ulcer, peptic ulcer, gastro-oesophageal reflux, reflux oesophagitis, and Helicobacter pylori eradication.
Mr. M Ramesh, EVP – Global Business Development - Mankind Pharma Limited, said, “This non-exclusive patent license agreement with Takeda aligns with our commitment to bringing innovative and effective treatments to patients in India. By introducing Vonoprazan, we aim to address a significant medical need and improve the quality of life for those suffering from acid-related illnesses with a new and advanced option for managing acid-related disorders, potentially offering improved health outcomes and quality of life.”
Read Also : Secretary, MoPNG visited RE Pavilion at IEW 2025, hosted by HPCLAbout Mankind Pharma
About Mankind Pharma Mankind Pharma (BSE: 543904 | NSE: MANKIND is one of the largest pharmaceutical company in India, which focuses on the domestic market with its Pan India presence. Mankind operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices. The company is a leading player in the domestic pharmaceuticals business present across acute and chronic therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, antidiabetic, neuro/CNS, VMN and respiratory, among others with a strategy to increase chronic presence going ahead. In the consumer healthcare business, the company operates in the condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements and anti-acne preparations categories, among others, with several category-leading brands. The company has 30 manufacturing facilities in India manufacturing a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products. Mankind has a consistent track record of product innovation through 6 dedicated R&D facilities backed by more than 660 scientists.
News Must Read
- Bank of India Raises Rs 2,690 Crore through 10-Year Infrastructure Bonds
- SOCAR, MRPL and ONGC Sign Strategic MoU at India Energy Week 2025
- India signed multiple strategic agreements and MoUs at IEW 2025
- HAL and IIIT Dharwad Sign MoU for Collaborative Research and Skill Development
- GAIL and Cummins sign MoU for collaboration on clean energy at IEW 2025
- Banks to remain open on 31st March, RBI cancels Holiday
- Tata Power Renewable and ONGC collaborated to explore battery energy storage
- BHEL secures order for 2x660 MW Koradi Thermal Power Station in Maharashtra
- ONGC and Tata Power Renewable Energy Limited Sign MoU
- BPCL sign landmark Crude Oil Deal with Petrobras